You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
European Medicines Agency committee recommends Pfizer's arthritis drug
Street Talk Episode 41 - How to Win the Funding Battle, Use Fintech to Play Offense
Forward Spark Spreads Suggest Rising Profitability Of US Renewables As Sector Matures
MA Activity The Big Story In Mature Online Video Platform Market
Martina Cheung Backs The Quality Program
The European Medicines Agency's Committee for Medicinal Products for Human Use made a recommendation in favor of Pfizer Inc.'s Lifmior to treat rheumatoid arthritis and other forms of arthritis, as well as plaque psoriasis.
The drug is identical to Amgen's Enbrel, which was authorized in the EU in 2000. Lifmior is still subject to approval by the European Commission.